Christine Janson

Bring your burning questions to this closing panel with all the seminar day’s presenters. With all ADC pharmacology topics up for discussion, hear the speakers delve into mechanistic and PD investigation for traditional and novel ADCs to model and characterize the next wave of ADCs heading to the clinic.

Discussion Highlights Include:

• Exploring how pharmacology and mechanistic investigations can strengthen existing ADC knowledge and influence future ADC development
• Debating the therapeutic properties of conditionally active and masked ADCs to assess their ability to differentiate against traditional ADC profiles
• Discussing computational modelling and PK/PD approaches to tackle translational considerations for noncytotoxic payload and novel format ADCs

• Breaking down design of XB404 leveraging Adagene and SMARTag platforms to develop a masked ADC targeting ROR1/2
• Emphasizing rationale of XB404 masked mechanism to minimize on target, off tumor safety in ROR1/2 expressing tumors
• Laying out preclinical characterization across in vitro cytotoxicity and bystander activity and in vivo efficacy in CDX and PDX models